GENETIC TECHNOLOGIES LIMITED — Board/Management Information 2003

Aug 28, 2003

29 August 2003

The Manager Company Announcements Office Australian Stock Exchange Limited Exchange Centre 20 Bridge Street Sydney NSW 2000

Dear Sir.

Professor Colin L. Masters joins GTG Scientific Advisory Committee

As previously announced Genetic Technologies Limited (ASX:GTG) is establishing a Scientific Advisory Committee.

GTG is now pleased to announce the appointment of leading neuroscientist and diagnostic pathologist, Professor Colin L. Masters, to the Company's Scientific Advisory Committee. His principal role will be to advise the Company on the implementation of genetic-based testing and management of brain disorders such as dementia, which affects tens of millions of people globally.

Professor Masters is an internationally-acclaimed neuroscientist who holds a prestigious Fellowship of the Australian Academy of Sciences, in recognition of his ground-breaking research in the fields of Alzheimer's disease and other neurodegenerative and neuropsychiatric disorders. He is the author of over 500 scientific papers, and the recipient of multiple international awards and prizes, including the King Faisal International Prize in Medicine, the Mayne Florey Medal, the American Academy of Neurology Potamkin Prize and the Max Plank Research Award.

Professor Masters is a Fellow of the Royal College of Pathologists of Australasia, and a Fellow of the Royal College of Pathologists of Great Britain. He is the former Chair of Pathology at the University of Melbourne, and now holds one of the few Laureate

Professorships at that institution. He is the Chief Scientific Advisor to Neuroscience Australia and holds several appointments as a consultant diagnostic pathologist.

Professor Masters is on numerous national and international advisory panels on Alzheimer's disease and other causes of memory loss, and has been an advisor to several governments on transmissible brain degenerative diseases, including "Mad Cow" disease.

Professor Masters has consulted widely for several major pharmaceutical companies, and is also an Executive Director of Prana Biotechnology, as well as Chairman of the Prana Scientific Advisory Board.

It is an honour for the Company to have someone as distinguished as Professor Masters as a high-level advisor to our organisation. Professor Masters is an outstanding Australian who is globally recognized for his scientific achievements and his achievements in public health. We anticipate that he will be a key driver of our genetic testing program, now and in the future.

Yours faithfully,

Dr Mervyn Jacobson Executive Chairman